spacer
home > pmps > autumn 2008 > rubber stoppers: delivering safe sterile components
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Rubber Stoppers: Delivering Safe Sterile Components

Supplying ‘ready-to-use’ primary packaging components is the logical follow-up to supplying ‘ready-to-sterilise’ components. By transferring washing and sterilisation operations to the supplier, this concept gives greater flexibility to pharmaceutical laboratories. Delegating a key operation like sterilisation requires the highest degree of quality assurance, and it is the responsibility of the supplier to guarantee the sterility of the parts it supplies. Obtaining sterile components requires mastery of all the applicable pharmaceutical requirements, control over the process before irradiation, and a validation procedure to ensure effective sterilisation.

MASTERY OF THE PRODUCTION PROCESS BEFORE IRRADIATION

Sterile, ‘ready-to-use’ products, whether stoppers or plungers, undergo a specific manufacturing process before being sterilised by gamma radiation...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals enters into manufacturing agreement with the Swedish company Affibody

[Noáin, May 27, 2019] 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics, has signed a collaboration agreement with the Swedish company Affibody for the process transfer, scale-up and GMP commercial manufacturing of a recombinant protein sole property of Affibody.
More info >>

White Papers

Streamlining patient recruitment using EHR data

The field of (bio)pharmaceutical research is booming. Increasingly more innovative therapeutics are being developed with the ability to drastically improve the quality of life of millions of patients around the world. Rigorously testing each of these candidate drugs for their safety and efficacy is an essential part of the development process. As the number of clinical trials steadily increases, the search for patients who present a specific medical profile and are willing to participate intensifies.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement